Serum IL 26 as a Marker of Disease Activity in SLE

Launched by ASSIUT UNIVERSITY · Dec 16, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a substance called Interleukin 26 (IL-26) in the blood of patients with Systemic Lupus Erythematosus (SLE), a type of autoimmune disease where the body's immune system attacks its own tissues. The researchers want to see if the levels of IL-26 can help them understand how active or severe the disease is in these patients compared to healthy individuals.

To be eligible for this study, participants must be adults diagnosed with SLE according to specific criteria. However, individuals with other autoimmune diseases like rheumatoid arthritis or scleroderma will not be included. While the trial is not yet recruiting participants, once it begins, those who take part will provide blood samples to help researchers gather important information about IL-26 and its connection to SLE. This could lead to better ways to monitor the disease and improve treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult SLE Patients who fulfilled the 2012 systemic lupus international collaborating clinics (SLICC) criteria
• Exclusion Criteria:
• • Individuals with other autoimmune diseases (rheumatoid arthritis dermatomyositis, scleroderma, mixed connective tissue disease).